Gene
FRS2
FRS2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (4), Actionable biomarkers (1), Trial mentions (2), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FRS2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
FRS2 has 2 trial mentions across 2 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 3 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 3 of 13,598 | 0.02% |
| 2021 | 0 of 8,692 | 0.00% | 2 of 15,045 | 0.01% |
| 2020 | 0 of 7,640 | 0.00% | 1 of 14,459 | 0.01% |
| 2019 | 1 of 7,300 | 0.01% | 7 of 12,159 | 0.06% |
| 2018 | 0 of 6,927 | 0.00% | 3 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 2 of 11,595 | 0.02% |
Showing 10 of 37 years.
Assay-provider ledger (4)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| ABBOTT | Context dependent | Clinical validation | 1 | August 01, 2019 |
| QIAGEN | Reagent supplier | Clinical validation | 1 | August 01, 2019 |
| ROCHE | Context dependent | Clinical validation | 1 | August 01, 2019 |
| RNAmeTRIX | Diagnostic provider | Clinical validation | 1 | October 01, 2012 |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FRS2 amplification | Fgfr Inhibitors | response-associated | liposarcoma | Cancer Genome Interpreter |
Trial mentions (2)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04071184 | Trial eligibility (AACT) |
| NCT01732107 | Trial outcomes (AACT) |
Target-disease associations (74)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| BMI-adjusted hip circumference | measurement | GWAS credible sets |
| BMI-adjusted waist circumference | measurement | GWAS credible sets |
| Genetic central nervous system malformation | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Meckel syndrome, type 4 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Moderate albuminuria | phenotype | GWAS credible sets |
Showing 5 of 74 associations.
Vendor sourcing (9)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.971G>A (p.R324H) alteration is located in exon 10 (coding exon 5) of the FRS2 gene. This alteration results from a G to A substitution at nucleotide po... | View ClinVar record SCV003536815.2 |
| Hoosier Cancer Research Network (United States) | Trial collaborator | Exploratory endpoint in a trialTrial endpoint | Characterize Pre- and Post-treatment VEGFR Pathway Phosphorylation Changes as Assessed by Bladder Tumor Tissue Immunohistochemistry. | View trial NCT01732107 |
| Hoosier Cancer Research Network (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | FRS2 | View trial NCT01732107 |
| Noah Hahn, M.D. | Trial sponsor | Exploratory endpoint in a trialTrial endpoint | Characterize Pre- and Post-treatment VEGFR Pathway Phosphorylation Changes as Assessed by Bladder Tumor Tissue Immunohistochemistry. | View trial NCT01732107 |
| Noah Hahn, M.D. | Trial sponsor | Mentioned in trial textTrial free-text mention | FRS2 | View trial NCT01732107 |
Showing 5 of 9 sourcing records.
Trial-cited literature (36)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. | Annals of oncology : official journal of the European Society for Medical Oncology | 2023 | 98 |
| Prenatal social support in low-risk pregnancy shapes placental epigenome. | BMC medicine | 2023 | 11 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. | Cancer discovery | 2022 | 83 |
| FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. | Endocrine | 2022 | 13 |
Showing 5 of 36 papers.
Literature-extracted relations (5)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Sorafenib | Chemical | associate |
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. | 2015 |
| Lung Neoplasms | Disease | associate |
A combinatorial strategy for treating KRAS-mutant lung cancer. | 2016 |
| Neoplasms | Disease | associate |
A combinatorial strategy for treating KRAS-mutant lung cancer. | 2016 |
| Calcinosis Cutis | Disease | associate |
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. | 2015 |
| Carcinoma, Renal Cell | Disease | associate |
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. | 2015 |
Organizations publishing (56)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 5 | 2011 to 2023 |
| Harvard Medical School | Academic | 4 | 2019 to 2023 |
| Mass General Brigham | Hospital | 3 | 2015 to 2022 |
| Max Planck Society | Nonprofit | 2 | 2010 to 2015 |
| Mount Sinai Health System | Hospital | 2 | 2018 to 2022 |
Showing 5 of 56 organizations.
Where FRS2 appears
- cancer or benign tumor
- cardiovascular disease
- endocrine system disease
- genetic, familial or congenital disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
72 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.